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ABSTRACT
BACKGROUND: Rheumatoid arthritis (RA) is one of the most common chronic infl ammatory diseases. It main-
ly involves the joints and also affects directly or indirectly nearly all organ systems. The question whether RA 
causes exocrine pancreatic disfunction remains unclear. The purpose of this study is to evaluate whether or not 
RA contributes to pancreatic exocrine insuffi ciency. This was done by ruling out seconder Sjögren’s syndrome 
(SjS) by using Schirmer’s test.
METHODS: A total of 60 patients (20 RA, 20 RA + SjS and 20 SjS) and 20 healthy volunteers were included in 
the study. Patients with RA who had not undergonethe Schirmer’s test in the last 6 months and all healthy vol-
unteers included in the study underwent the Schirmer’s test at an outpatient clinic. Random fecal samples were 
taken from all participants and fecal pancreatic elastase was measured to evaluate pancreatic exocrine functions.
RESULTS: In the study, a statistically signifi cant difference was found between the control group,SjS and RA+SjS 
groups. But there was no signifi cant difference between the control group and RA group. In RA group, fecal 
elastase levels were statistically signifi cantly higher compared to the SjS group. But there was no signifi cant 
difference between RA+SjS and SjS groups.
CONCLUSION: Fecal elastase signifi cantly decreased in SjS compared to the normal population while pancre-
atic exocrine functions are considered to be impaired in SjS. There are also impaired pancreatic exocrine func-
tions in the secondary SjS associated with RA. Consequently, pancreatic exocrine dysfunction, which can be 
seen in patients with RA, may be thought to be caused by secondary SjS associated with RA (Tab. 6, Fig. 1,
Ref. 19). Text in PDF www.elis.sk.
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Introduction
Although it is defi ned as a joint disease, RA has systemic 
manifestations. Extraarticular fi ndings of RA are seen in 18–40 
% of patients and are associated with worsened prognosis (1). The 
disease affects directly or indirectly nearly all organ systems, while 
causing a wide range of health issues from cardiovascular and re-
spiratory problems to infections, depression and gastrointestinal 
ulcers (2). In an autopsy study conducted by Belly et al., acute 
pancreatitis was found in 6 out of 60 RA patients while chronic 
pancreatitis was found in 15 of them (3). In another study, the in-
cidence of acute pancreatitis in RA patients was found in 185.7 
per 100,000 person-years and excess risk of 1.62 compared with 
non-RA patients (2). However, Michaud et al. found that there was 
no evidence of increased rate of pancreatitis in RA (4).
The main histological feature is the lymphocytic infi ltration 
of the salivary and ocular glands. Xerophthalmia is a major fi nd-
ing. The signs may be seen in various systems other than exo-
crine glands, including skin, muscle, veins, joints, internal organs, 
blood and lymphatic system of 1/3 of the patients (5, 6). Afzelius 
and colleagues observed in their study that 25 % of the patients 
had morphological changes of the pancreas as evaluated by se-
cretin-stimulated magnetic resonance cholangiopancreatography 
(MRCP), and two patients had chronic pancreatitis-like changes 
(7). In another study, the authors evaluated pancreatic functions 
by fecal elastase-1 test in 50 chronic polyarthritis cases. They 
found that two cases (4 %; 95% confi dence interval, 1–14 %) had 
abnormally low fecal elastase level (8). 
The main clinical fi nding of the exocrine pancreatic disorder 
is fat malabsorption. Patients suffer from weight loss, uncomfort-
able and bloating feeling in the abdomen. The diagnosis is based 
on clinical symptoms and assessment of direct and indirect tests 
(9). Indirect pancreatic function tests have lower sensitivity but 
higher applicability compared to direct tests. (10). The fecal elas-
tase test is more sensitive and specifi cally refl ects the pancreatic 
exocrine function, compared to other indirect tests although it does 
not achieve high specifi city and sensitivity of direct function tests 
(11). Sensitivity and specifi city of fecal elastase test were found 
to be 93 % when cut-off value is accepted as < 200 μg/g (12). The 
purpose of this study is to evaluate whether or not RA contributes 
to pancreatic exocrine insuffi ciency. This is done by ruling out 
secondary SjS by using Schirmer’s test.
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Methods
A total of 60 patients (20 RA, 20 RA + SjS and 20 SjS) and 20 
healthy volunteers, who applied to our rheumatology outpatient 
clinic and met the criteria mentioned below were included in the 
study. Signed written consent was taken from the participants of 
the study, and the approval of the ethics committee of Başkent 
University was obtained. Inclusion criteria for RA patients: (i) 
patients younger than 60 years, (ii) duration of the disease > 1 
year, (iii) detection of Schirmer’s test result > 15 mm or ≤ 5 mm 
in the last 6 months. Inclusion criteria for SjS patients: (i) pa-
tients younger than 60 years, (ii) duration of the disease > 1 year. 
Inclusion criteria for control group: (i) patients younger than 60 
years, (ii) Schirmer’s test > 15 mm, (iii) volunteers without sys-
temic disease. Excluded from the study were conditions that affect 
pancreatic exocrine functions and Schirmer’s test results, namely 
chronic pancreatitis, pancreatic cancers, pancreatic resections, 
gastrointestinal surgeries, diabetes mellitus, cystic fi brosis, amyloi-
dosis, gluten enteropathy, periampullary tumors, Zollinger Ellison 
syndrome, Crohn’s disease, short bowel syndrome, antidepressant, 
anticholinergic, neuroleptic, clonidine, diuretic use, granulomatous 
diseases (sarcoidosis, tuberculosis, leprosy), therapeutic radiation, 
head and neck trauma and surgery, dehydration, and patients over 
60 years of age (except patients with SjS who were diagnosed with 
biopsy). The patients involved in the study were questioned about 
the duration of the illness, accompanying diseases, and the drugs 
they use. Abdominal ultrasonography was performed to evaluate 
the pancreatic morphology of the patients. The Schirmer’s test 
was carried out in patients with RA who had not undergone it in 
the last 6 months and all control patients included in the study at 
the outpatient clinic. A 5-mm wide Whatman fi lter paper No 41 
was placed inside the lateral third of the lower eyelid without an-
esthesia. The amount of moisture within the paper was measured 
after 5 minutes. If the moisture was ????? mm or less, the eye was 
considered “dry” (secondary SjS); if it was more than 15 mm, the 
result of Shirmer’s test was considered normal. According to the 
Schirmer’s test results, patients were divided into 2 groups. Patients 
with RA who were diagnosed as having the Schirmer’s test 5 mm 
or less were accepted as SjS associated with RA (Group RA + SjS). 
Random fecal samples were taken from all participants and 
stored at −20 °C until elastase measurement. Fecal pancreatic 
elastase was measured with a commercially avaliable ELISA test 
(Pancreatic Elastase ELISA; Bioserv Diagnostic GmbH, Rostock 
Germany), according to the manufacturer’s instructions. Serum 
CRP levels were measured simultaneously with the fecal sample.
Statistical analysis
Baseline characteristics and fecal elastase results for all sub-
jects and groups were given as mean (± standard deviation), me-
dian (smallest-highest), or median (width between quarters) for 
appropriate variables after normal distribution tests of the data had 
been performed. The categorical variables are given as number 
(percentage). The Kruskal–Wallis variance analysis test was used 
for inferential statistics between the disease groups and control 
group, while Mann–Whitney-U test was used for the binary com-
parison of drug use. Pearson / Spearman correlation coeffi cients 
were given in the correlation analysis with variables affecting the 
fecal elastase level. Multiple regression analysis was performed to 
examine the relationship of fecal elastase levels between groups 
independently of age. The SPSS program (Version 17, IBM SPSS 
Statistics, IBM Corporation, NY, USA) was used for calculations. 
p values < 0.05 were considered statistically signifi cant. 
Results
The mean age of the patients included in the study was 49.2 ± 
7.9 years in the RA group, 52.3 ± 6.6 years in the RA + SjS group, 
51.0 ± 11.3 years in the SjS group, and 44.5 ± 9.8 years in the con-
trol group. There was a statistically signifi cant difference between 
the mean ages of control group and RA group (Tab. 1). The dura-
tion of disease was 1.2 (0–5) years in SJS group, 6 (1–25) years 
in RA + SjS group and 7 (1–25) years in RA group.
When fecal elastase values were compared according to sex, 
mean fecal elastase level in males was 643.0 ± 134.4 μg/g and 
mean fecal elastase level in females was 666.1 ± 234.6 μg/g. It was 
observed that sex did not affect fecal elastase levels (p = 0.799) 
(Tab. 2). When fecal elastase levels were measured in all groups, 
the median fecal elastase was 750.5 μg/g in the control group, 
628.5 μg/g in SjS group, 577.5 ug/g in RA + SjS group, and 802.5 
μg/g in RA group. Statistically signifi cant differences were found 
Groups Agemean±SD 
Gender 
M/F
Control 44.5±9.8c 3/17
SjS 51.0±11.3 1/19
RA+SjS 52.3±6.6c 3/17
RA 49.2±7.9 0/20
p 0.044a 0.126
SD: Standart Deviation, M: Male, F: Female, a: One-Way ANOVA, b: Chi-square 
test, c: The difference between the control group and the RA+SjS group was statis-
tically signifi cant (p=0.039)
Tab. 1. Evaluation of age and gender distribution by groups.
Variables Fecal Elastase (μg/g)mean±SD p
Gender
Male (n=7) 643.0±134.4 0.799Female (n=73) 666.1±234.6
SD: Standard Deviation
Tab. 2. Evaluation of fecal elastase levels according to gender.
Groups Fecal Elastase (μg/g)median (WBQ)
Control (n:20) 750.5 (88.5)b,c
SjS (n:20) 628.5 (402.0)b,d
RA+SjS (n:20) 577.5 (371.5)c
RA (n:20) 802.5 (433.7)d
p a 0.034
WBQ: Width Between Quartiles, a: Kruskal Wallis test, b: The difference between 
the control group and the SjS group was statistically signifi cant (p = 0.006), c: The 
difference between the control group and the RA+SjS group was statistically sig-
nifi cant (p = 0.037), d: The difference between the SjS group and the RA group was 
statistically signifi cant (p = 0.013)
Tab. 3. Evaluation of fecal elastase levels according to the groups.
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between the control group and SjS group (p = 0.006) as well as 
between the control group and RA + SjS group (p = 0.037). In 
the RA group, fecal elastase levels were statistically higher than 
in SjS group (p = 0.013). The difference between RA + SjS and 
RA groups was not statistically signifi cant (p = 0.07) (Tab. 3).
When adjusted for age, it was observed that the level of fecal 
elastase in the SjS group was lower compared to the control group 
(p = 0.006). When adjusted for age, the level of fecal elastase in 
the RA+SjS group was not statistically signifi cant (p = 0.059). The 
similarity between the control group and RA group was also ob-
served when age-adjusted correction was made (p = 0.558) (Tab. 4).
There was no signifi cant correlation between age and fecal 
elastase levels in our study (r = –0.146; p = 0.195). There was no 
signifi cant correlation between disease duration and fecal elastase 
level (r = 0.093; p = 0.479). There was no signifi cant correlation 
between CRP and fecal elastase levels (r = –0.167; p = 0.139). The 
results are given in Table 5.
Discussion
RA is one of the most common chronic infl ammatory diseases. 
Although the disease mainly involves the joints, it also causes extra-
articular manifestations (13). SjS is a chronic infl ammatory autoim-
mune disease that predominantly involves exocrine glands. It can 
occur in conjunction with other autoimmune disorders and RA is the 
most common connective tissue disease associated with SjS (14). 
Studies investigating pancreatic exocrine dysfunction have 
been performed on patients with SjS mostly in rheumatol-
ogy. In a study conducted by Sumii T. et al., pancreatic exo-
crine functions (reduction in bicarbonate secretion) were inves-
tigated by performing a secretin stimulation test in patients with 
SjS (15). In this study, it was concluded that the decrease in 
bicarbonate secretion was characteristic. In another study con-
ducted by Candellli and his colleagues, pancreatic exocrine 
functions were assessed by fecal chymotrypsin test and it was 
found that in patients with SjS, exocrine functions were sta-
tistically signifi cantly lower than in the control group. It was 
also found that this was parallel to Schirmer test results (16). 
In this study, in the group of patients with SjS, the mean elas-
tase level was 562.50 μg/g, and there was a statistically sig-
nifi cant difference compared to control group. This result has 
been evaluated as SjS that affects pancreatic exocrine functions.
In the literature, there are also studies on pancreas functions 
and relationship with disease duration in SjS. In a study, PABA 
test, serum immunoreactivity trypsin levels and fecal fat measure-
ment tests were performed in primary and secondary SjS and it 
was found that pancreatic dysfunction is more severe in long-term 
disease (17). In another study, serum immunoreactive trypsin levels 
were found to be higher in primary SJS compared to secondary SjS, 
and the disorder was more frequent in cases with disease duration 
over 10 years. However, there was no clinical pancreatitis in any 
of pancreatic exocrine dysfunction cases. (18). In our study, no 
Variables
Regression
Coeffi cient (B) p
95% Confi dence Interval (B)
Lower Limit Upper Limit
SjS −0.378 0.006 −0.646 −0.109
RA+SjS −0.261 0.059 −0.533 0.011
RA −0.088 0.511 −0.352 0.177
Age −0.003 0.558 −0.013 0.007
Tab. 4. Examination of the effects of SjS, RA + SjS and RA groups ac-
cording to the control group on the fecal elastase level when the age 
correction was performed.
Variables R p
Age −0.146 0.195
Duration of disease 0.093 0.479
CRP −0.167 0.139
Tab. 5. Correlation coeffi cient and signifi cance levels between age, 
duration of disease and CRP, fecal elastase.
Variables Fecal Elastase (μg/g)Mean±ss p
NSAID 0.542
positive (n=38) 617.7±238.3
negative (n=22) 658.1±259.0
CORTICOSTEROIDS 0.112
positive (n=43) 600.9±237.3
negative (n=17) 712.5±252.1
PPI 0.948
positive (n=33) 634.4±217.2
negative (n=27) 630.3±279.0
HCQ 0.266
positive (n=16) 582.4±183.0
negative (n=44) 650.8±263.1
MTX 0.674
positive (n=36) 621.6±233.6
negative (n=24) 649.0±264.8
SLZ 0.145
positive (n=46) 607.0±232.1
negative (n=14) 716.4±274.6
LEFLUNOMID 0.964
positive (n=54) 633.0±253.2
negative (n=6) 628.2±164.5
NSAID: Nonsteroid anti-infl ammatory drugs, PPI: Proton pump inhibitors, HCQ: 
Hydroxychloroquine, MTX: Methotrexate, SLZ: Sulfasalazine
Tab. 6. Evaluation of fecal elastase levels according to drugs.
Fig. 1. Fecal elastase levels according to the groups.
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statistically signifi cant relationship was found between the dura-
tion of disease and pancreatic functions (p = 0.479). There was 
no clinical pancreatitis in our patients either. 
There are also studies in the literature investigating the effect 
of RA on pancreatic exocrine functions. In a study conducted by 
Gobelet et al, pancreatic exocrine functions were investigated by 
PABA test which was abnormal in 37.5 % of SjS and 35 % of RA, 
with no abnormalities in the control group (19). In our study, no 
statistically signifi cant difference was found between the control 
group and RA group in which the secondary SjS was excluded 
(p = 0.776). 
In our study, mean fecal elastase levels of patients were 666.1 
± 234.6 μg/g in women and 643.0 ± 134.4 μg/g in men. There 
was no statistical difference in mean fecal elastase levels between 
women and men ( p = 0.799). There was no statistically signifi cant 
correlation between fecal elastase and age (p=0.195) either. There 
was no statistically signifi cant relationship between pancreatic exo-
crine function and drugs used by the patients, e.g. methotrexate, 
sulfasalazine, hydroxychloroquine, lefl unomide, corticosteroids, 
proton pump inhibitors, nonsteroidal antiinfl ammatory drugs. 
There was no signifi cant association between pancreatic exocrine 
functions and CRP levels in our study. 
The best cut-off value for fecal elastase level was determined 
to be 200 μg/g. The fecal elastase results of 2 (2.5 %) of the pa-
tients in our study were found to be below 200 μg/g. It is known 
that fecal elastase is a sensitive test for detecting moderate and 
severe pancreatic insuffi ciency. Therefore, it can be assumed that 
other patients might have slightly exogenous pancreatic exocrine 
dysfunction or that fecal elastase 1 levels might have a different 
cut-off value for autoimmune diseases. Controlled studies involv-
ing a larger number of patients with long-term follow-up are nec-
essary to be able to conclude in this decision. 
In our study, fecal elastase levels in SjS and RA+SjS groups 
were statistically signifi cantly lower than those of the control 
group. Fecal elastase levels in the RA group and control group 
were similar. In accordance with literature, these results have also 
shown that pancreatic exocrine functions were impaired in SjS. 
Pancreatic exocrine function was also impaired in the secondary 
SjS associated with RA. But there was no pancreatic exocrine dys-
function in patients with RA without concommitant secondary SjS. 
These results suggest that impaired pancreatic exocrine function 
in RA patients may be caused by secondary SjS associated with 
RA. However, for better understanding of the pancreatic exocrine 
dysfunctions seen in RA, long-term and controlled studies involv-
ing a larger number of patients are necessary.
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